Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.

Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.

The present invention relates to a plasticizer composition and a preparation method therefor and, more specifically, to a plasticizer composition, which contains an anhydrosugar alcohol monoester, an anhydrosugar alcohol diester, and a sugar alcohol ester at a specific content ratio and has improved plasticity and excellent storage stability, and to a preparation method therefor.

The present invention relates to a plasticizer composition and a preparation method therefor and, more specifically, to a plasticizer composition, which contains an anhydrosugar alcohol monoester, an anhydrosugar alcohol diester, and a sugar alcohol ester at a specific content ratio and has improved plasticity and excellent storage stability, and to a preparation method therefor.

The present invention relates to alkynyl-substituted N-phenylpyrrolidine-2,4-diones according to the general formula (I) or agrochemically acceptable salts thereof, ##STR00001##
where X=C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-haloalkyl or C.sub.3-C.sub.6-cycloalkyl, Y=C.sub.1-C.sub.4-alkyl or C.sub.3-C.sub.6-cycloalkyl, R.sup.1=hydrogen, C.sub.1-C.sub.6-alkyl, or C.sub.3-C.sub.6-cycloalkyl, R.sup.2=hydrogen or methyl, R.sup.3=C.sub.1-C.sub.6-alkyl or C.sub.1-C.sub.6-alkoxy-C.sub.2-C.sub.6-alkyl, G=hydrogen, a cleavable group L or a cation E. The invention further relates to a herbicidal composition comprising a compound of the general formula (I) and to the use of the compounds according to the invention for controlling weeds and weed grasses in crops of useful plants.

The present invention relates to the use of an ether or an ester of a 1-substituted cycloalkanol or of mixtures of two or more ethers or esters of 1-substituted cycloalkanols or of a stereoisomer thereof or of a mixture of two or more stereoisomers thereof as aroma chemicals; to the use thereof for modifying the scent character of a fragranced composition; to an aroma chemical composition containing an ether or an ester of a 1-substituted cycloalkanol or of mixtures of two or more ethers or esters of 1-substituted cycloalkanols or of a stereoisomer thereof or of a mixture of two or more stereoisomers thereof; and to a method of preparing a fragranced composition or for modifying the scent character of a fragranced composition. The invention further relates to specific ethers or esters of 1-substituted cycloalkanols.

The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

A process for manufacturing an aqueous hydrogen peroxide solution comprising the following steps:—hydrogenating a working solution which comprises an alkylanthraquinone and/or tetrahydroalkylanthraquinone and a mixture of a non-polar organic solvent and a polar organic solvent;—oxidizing the hydrogenated working solution to produce hydrogen peroxide; and—isolating the hydrogen peroxide, wherein the polar organic solvent is 5-methyl-2-isopropylcyclohexanecarbonitrile (C11F).

A process for manufacturing an aqueous hydrogen peroxide solution comprising the following steps:—hydrogenating a working solution which comprises an alkylanthraquinone and/or tetrahydroalkylanthraquinone and a mixture of a non-polar organic solvent and a polar organic solvent;—oxidizing the hydrogenated working solution to produce hydrogen peroxide; and—isolating the hydrogen peroxide, wherein the polar organic solvent is 5-methyl-2-isopropylcyclohexanecarbonitrile (C11F).